Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Among 886 patients with advanced renal-cell cancer, median progression-free survival was 13.8 months among those assigned to avelumab plus axitinib and 7.2 months among those assigned to sunitinib. Toxic effects of grade 3 or higher were similar in the two groups.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-03, Vol.380 (12), p.1103-1115
Hauptverfasser:	Motzer, Robert J, Penkov, Konstantin, Haanen, John, Rini, Brian, Albiges, Laurence, Campbell, Matthew T, Venugopal, Balaji, Kollmannsberger, Christian, Negrier, Sylvie, Uemura, Motohide, Lee, Jae L, Vasiliev, Aleksandr, Miller, Wilson H, Gurney, Howard, Schmidinger, Manuela, Larkin, James, Atkins, Michael B, Bedke, Jens, Alekseev, Boris, Wang, Jing, Mariani, Mariangela, Robbins, Paul B, Chudnovsky, Aleksander, Fowst, Camilla, Hariharan, Subramanian, Huang, Bo, di Pietro, Alessandra, Choueiri, Toni K
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Axitinib - administration & dosage Axitinib - adverse effects Body weight Cancer therapies Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Drug dosages Evidence-based medicine Female Humans Immunotherapy Inhibitor drugs Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kinases Male Middle Aged Monoclonal antibodies Oncology PD-L1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Progression-Free Survival Renal cell carcinoma Single-Blind Method Sunitinib - adverse effects Sunitinib - therapeutic use Survival Rate Targeted cancer therapy Tumors Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among 886 patients with advanced renal-cell cancer, median progression-free survival was 13.8 months among those assigned to avelumab plus axitinib and 7.2 months among those assigned to sunitinib. Toxic effects of grade 3 or higher were similar in the two groups.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1816047